News | February 03, 2025
Jubilant Pharmova Q3 FY25 revenue up 9%
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
To accelerate the development of next-generation radioconjugates to treat cancer
Subscribe To Our Newsletter & Stay Updated
